A Facile Approach for Synthesis and Intracellular Delivery of Size Tunable Cationic Peptide Functionalized Gold Nanohybrids in Cancer Cells

2018 ◽  
Vol 29 (4) ◽  
pp. 1102-1110 ◽  
Author(s):  
Kavita Bansal ◽  
Mohammad Aqdas ◽  
Munish Kumar ◽  
Rajni Bala ◽  
Sanpreet Singh ◽  
...  
2014 ◽  
Vol 35 (9) ◽  
pp. 888-894 ◽  
Author(s):  
Renjith P. Johnson ◽  
Young-Il Jeong ◽  
Johnson V. John ◽  
Chung-Wook Chung ◽  
Seon Hee Choi ◽  
...  

2019 ◽  
Vol 11 (5) ◽  
pp. 4719-4736 ◽  
Author(s):  
Abhijit Biswas ◽  
Kasturee Chakraborty ◽  
Chiranjit Dutta ◽  
Sanchita Mukherjee ◽  
Paramita Gayen ◽  
...  

2018 ◽  
Vol 19 (9) ◽  
pp. 3725-3737 ◽  
Author(s):  
Tilahun Ayane Debele ◽  
Lu-Yi Yu ◽  
Cheng-Sheng Yang ◽  
Yao-An Shen ◽  
Chun-Liang Lo

1999 ◽  
Vol 5 (S2) ◽  
pp. 392-393
Author(s):  
Joan F. Karr ◽  
Robert P. Apkarian ◽  
John A. Petros

Transfection of mammalian cells can be enhanced by forming complexes between exogenous DNA and cationic peptides which facilitate DNA transport through cell membranes. Although complexes of plasmid DNA and cationic peptides have been characterized by microscopy, little is known about the complexes formed between oligonucleotides (ODN) and cationic peptides or how the ultrastructure of these complexes affects the intracellular delivery via the cell membrane. Because ODN have potential as therapeutic reagents in the treatment of many diseases, there is a need to develop improved methods for effective delivery of these molecules. By analyzing molecular interactions between cationic peptides and ODN and their effects on cell membranes, cell viability, and DNA delivery, improved delivery compounds can be designed. In this paper, we compare the interactions of a 28 base ODN with three cationic peptides: a novel compound, MNLEK (H-Met-(Nle-Lys4)7-Nle-NH2), an established transfection reagent, poly(L-lysine) (∼ 54 kDa), and a recently described cationic peptide which delivers both plasmid DNA and antisense ODN to cells, KALA (WEAKLAKALAKALAKHLAKALAKALKACEA).For high resolution scanning electron microscopy (HRSEM), DU145 human prostate cancer cells were grown overnight on poly-(D-lysine) coated, UV irradiated silicon chips.


2013 ◽  
Vol 3 (1) ◽  
pp. 7 ◽  
Author(s):  
Anthony Stanislaus ◽  
Anil Philip Kunnath ◽  
Snigdha Tiash ◽  
Tahereh Fatemian ◽  
Nur Izyani Kamaruzman ◽  
...  

Cervical cancer is the second most common cancer and fourth leading cause of cancer-related deaths among women. Advanced stage of the disease is treated with radiation therapy and chemotherapy with poor therapeutic outcome and adverse side effects. NFκB, a well-known transcription factor in the control of immunity and inflammation, has recently emerged as a key regulator of cell survival through induction of antiapoptotic genes. Many human cancers, including cervical carcinoma, constitutively express NF-κB and a blockade in expression of its subunit proteins through targeted knockdown of the gene transcripts with small interfering RNAs (siRNA) could be an attractive approach in order to sensitize the cancer cells towards the widely used anti-cancer drugs. However, the inefficiency of the naked siRNA to cross the plasma membrane and its sensitiveness to nuclease-mediated degradation are the major challenges limiting the siRNA technology in therapeutic intervention. pH-sensitive carbonate apatite has been established as an efficient nano-carrier for intracellular delivery of siRNA, due to its strong electrostatic interaction with the siRNA, the desirable size distribution of the resulting siRNA complex for effective endocytosis and the ability of the endocytosed siRNA to be released from the degradable particles and escape the endosomes, thus leading to the effective knockdown of the target gene of cyclin B1 or ABCB1. Here, we report that carbonate apatite-facilitated delivery of the siRNA targeting NF-κB1 and NF-κB2 gene transcripts in HeLa, a human cervical adenocar- cinoma cell line expressing NF-κB, led to a synergistic effect in enhancement of chemosensitivity to doxorubicin, but apparently not to cisplatin or paclitaxel.


2014 ◽  
Vol 11 (8) ◽  
pp. 2777-2786 ◽  
Author(s):  
Fe-Lin Lin Wu ◽  
Tzyy-Harn Yeh ◽  
Ying-Luen Chen ◽  
Yu-Chin Chiu ◽  
Ju-Chen Cheng ◽  
...  

2014 ◽  
Vol 5 (16) ◽  
pp. 4627-4634 ◽  
Author(s):  
Thavasyappan Thambi ◽  
V. G. Deepagan ◽  
Hyewon Ko ◽  
Yung Doug Suh ◽  
Gi-Ra Yi ◽  
...  

To minimize the premature drug release of nanocarriers, we have developed chemically cross-linked bioreducible polymersomes (CLPMs) that can specifically release the drug inside cancer cells.


Sign in / Sign up

Export Citation Format

Share Document